CA2285298C - Complexes comprising local anesthetic and nucleic acid and method of making and using the same - Google Patents
Complexes comprising local anesthetic and nucleic acid and method of making and using the same Download PDFInfo
- Publication number
- CA2285298C CA2285298C CA 2285298 CA2285298A CA2285298C CA 2285298 C CA2285298 C CA 2285298C CA 2285298 CA2285298 CA 2285298 CA 2285298 A CA2285298 A CA 2285298A CA 2285298 C CA2285298 C CA 2285298C
- Authority
- CA
- Canada
- Prior art keywords
- nucleic acid
- local anesthetic
- dna
- individual
- protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000003589 local anesthetic agent Substances 0.000 title claims abstract description 138
- 150000007523 nucleic acids Chemical class 0.000 title claims abstract description 131
- 102000039446 nucleic acids Human genes 0.000 title claims abstract description 126
- 108020004707 nucleic acids Proteins 0.000 title claims abstract description 126
- 238000004519 manufacturing process Methods 0.000 title description 5
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 145
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 130
- 238000000034 method Methods 0.000 claims abstract description 70
- 239000000203 mixture Substances 0.000 claims abstract description 51
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 71
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 63
- 108020004414 DNA Proteins 0.000 claims description 62
- 150000001875 compounds Chemical class 0.000 claims description 44
- 150000003839 salts Chemical class 0.000 claims description 34
- 230000001717 pathogenic effect Effects 0.000 claims description 31
- 239000003814 drug Substances 0.000 claims description 29
- 244000052769 pathogen Species 0.000 claims description 29
- 229940079593 drug Drugs 0.000 claims description 28
- 229920001184 polypeptide Polymers 0.000 claims description 28
- 230000001225 therapeutic effect Effects 0.000 claims description 28
- 125000002091 cationic group Chemical group 0.000 claims description 24
- 230000008569 process Effects 0.000 claims description 23
- 229960003150 bupivacaine Drugs 0.000 claims description 17
- 206010028980 Neoplasm Diseases 0.000 claims description 16
- 201000010099 disease Diseases 0.000 claims description 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 16
- LEBVLXFERQHONN-UHFFFAOYSA-N 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide Chemical compound CCCCN1CCCCC1C(=O)NC1=C(C)C=CC=C1C LEBVLXFERQHONN-UHFFFAOYSA-N 0.000 claims description 15
- 230000003463 hyperproliferative effect Effects 0.000 claims description 15
- 201000011510 cancer Diseases 0.000 claims description 14
- 238000000502 dialysis Methods 0.000 claims description 14
- 239000013612 plasmid Substances 0.000 claims description 14
- 208000023275 Autoimmune disease Diseases 0.000 claims description 13
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 12
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 12
- 239000000427 antigen Substances 0.000 claims description 12
- 108091007433 antigens Proteins 0.000 claims description 12
- 102000036639 antigens Human genes 0.000 claims description 12
- 229910052757 nitrogen Inorganic materials 0.000 claims description 7
- 230000003612 virological effect Effects 0.000 claims description 6
- 125000001165 hydrophobic group Chemical group 0.000 claims description 4
- 230000028993 immune response Effects 0.000 abstract description 30
- 230000001939 inductive effect Effects 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 72
- 230000002163 immunogen Effects 0.000 description 49
- 229960005015 local anesthetics Drugs 0.000 description 43
- 230000002068 genetic effect Effects 0.000 description 23
- 239000012528 membrane Substances 0.000 description 23
- 150000002632 lipids Chemical class 0.000 description 22
- 230000007935 neutral effect Effects 0.000 description 21
- 210000004379 membrane Anatomy 0.000 description 19
- -1 prylocaine Chemical compound 0.000 description 18
- 238000004626 scanning electron microscopy Methods 0.000 description 18
- 239000000243 solution Substances 0.000 description 17
- 241000700605 Viruses Species 0.000 description 15
- 230000002209 hydrophobic effect Effects 0.000 description 15
- 229960005486 vaccine Drugs 0.000 description 15
- 230000002519 immonomodulatory effect Effects 0.000 description 14
- 230000001105 regulatory effect Effects 0.000 description 14
- 239000002245 particle Substances 0.000 description 13
- 239000003795 chemical substances by application Substances 0.000 description 12
- 239000002773 nucleotide Substances 0.000 description 12
- 125000003729 nucleotide group Chemical group 0.000 description 12
- 239000013543 active substance Substances 0.000 description 10
- 230000014509 gene expression Effects 0.000 description 10
- 230000008488 polyadenylation Effects 0.000 description 10
- 239000003599 detergent Substances 0.000 description 9
- 208000015181 infectious disease Diseases 0.000 description 9
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 8
- 125000000129 anionic group Chemical group 0.000 description 8
- 241000701022 Cytomegalovirus Species 0.000 description 7
- 230000003053 immunization Effects 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 241000894007 species Species 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 241000725303 Human immunodeficiency virus Species 0.000 description 6
- 239000007864 aqueous solution Substances 0.000 description 6
- 238000001415 gene therapy Methods 0.000 description 6
- 230000001976 improved effect Effects 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 238000002156 mixing Methods 0.000 description 6
- 239000008194 pharmaceutical composition Substances 0.000 description 6
- 230000001681 protective effect Effects 0.000 description 6
- 239000004094 surface-active agent Substances 0.000 description 6
- 108091026890 Coding region Proteins 0.000 description 5
- 241000711573 Coronaviridae Species 0.000 description 5
- 102000004127 Cytokines Human genes 0.000 description 5
- 108090000695 Cytokines Proteins 0.000 description 5
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 5
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 5
- 210000001744 T-lymphocyte Anatomy 0.000 description 5
- 108090000994 Catalytic RNA Proteins 0.000 description 4
- 102000053642 Catalytic RNA Human genes 0.000 description 4
- 239000013566 allergen Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 4
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000003623 enhancer Substances 0.000 description 4
- 239000005556 hormone Substances 0.000 description 4
- 229940088597 hormone Drugs 0.000 description 4
- 210000000987 immune system Anatomy 0.000 description 4
- 238000002649 immunization Methods 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- INWLQCZOYSRPNW-UHFFFAOYSA-N mepivacaine Chemical compound CN1CCCCC1C(=O)NC1=C(C)C=CC=C1C INWLQCZOYSRPNW-UHFFFAOYSA-N 0.000 description 4
- 238000005192 partition Methods 0.000 description 4
- 108091092562 ribozyme Proteins 0.000 description 4
- 238000001338 self-assembly Methods 0.000 description 4
- 238000010561 standard procedure Methods 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- 238000002255 vaccination Methods 0.000 description 4
- 230000007332 vesicle formation Effects 0.000 description 4
- 108020004705 Codon Proteins 0.000 description 3
- 102000053602 DNA Human genes 0.000 description 3
- 108010041986 DNA Vaccines Proteins 0.000 description 3
- 229940021995 DNA vaccine Drugs 0.000 description 3
- 241000709661 Enterovirus Species 0.000 description 3
- 241000283073 Equus caballus Species 0.000 description 3
- VTUSIVBDOCDNHS-UHFFFAOYSA-N Etidocaine Chemical compound CCCN(CC)C(CC)C(=O)NC1=C(C)C=CC=C1C VTUSIVBDOCDNHS-UHFFFAOYSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 102000013462 Interleukin-12 Human genes 0.000 description 3
- 108010065805 Interleukin-12 Proteins 0.000 description 3
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 3
- 241000714474 Rous sarcoma virus Species 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 230000000692 anti-sense effect Effects 0.000 description 3
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 210000000349 chromosome Anatomy 0.000 description 3
- 229960003976 etidocaine Drugs 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 229960004194 lidocaine Drugs 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 230000001766 physiological effect Effects 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 229960002372 tetracaine Drugs 0.000 description 3
- GKCBAIGFKIBETG-UHFFFAOYSA-N tetracaine Chemical compound CCCCNC1=CC=C(C(=O)OCCN(C)C)C=C1 GKCBAIGFKIBETG-UHFFFAOYSA-N 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- ZKMNUMMKYBVTFN-HNNXBMFYSA-N (S)-ropivacaine Chemical compound CCCN1CCCC[C@H]1C(=O)NC1=C(C)C=CC=C1C ZKMNUMMKYBVTFN-HNNXBMFYSA-N 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 2
- 102000007469 Actins Human genes 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 102000019034 Chemokines Human genes 0.000 description 2
- 108010012236 Chemokines Proteins 0.000 description 2
- 206010061041 Chlamydial infection Diseases 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 208000004232 Enteritis Diseases 0.000 description 2
- 241000282324 Felis Species 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 208000005577 Gastroenteritis Diseases 0.000 description 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 2
- 206010018693 Granuloma inguinale Diseases 0.000 description 2
- 108010054147 Hemoglobins Proteins 0.000 description 2
- 102000001554 Hemoglobins Human genes 0.000 description 2
- 241000711549 Hepacivirus C Species 0.000 description 2
- 241000700721 Hepatitis B virus Species 0.000 description 2
- 241000709721 Hepatovirus A Species 0.000 description 2
- 208000009889 Herpes Simplex Diseases 0.000 description 2
- 108020005350 Initiator Codon Proteins 0.000 description 2
- 102000003505 Myosin Human genes 0.000 description 2
- 108060008487 Myosin Proteins 0.000 description 2
- 241000713112 Orthobunyavirus Species 0.000 description 2
- 229930012538 Paclitaxel Natural products 0.000 description 2
- 241000125945 Protoparvovirus Species 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- 241000702263 Reovirus sp. Species 0.000 description 2
- 241000725643 Respiratory syncytial virus Species 0.000 description 2
- 241000606651 Rickettsiales Species 0.000 description 2
- 241000702670 Rotavirus Species 0.000 description 2
- 108091008874 T cell receptors Proteins 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- 102000040945 Transcription factor Human genes 0.000 description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
- 229940035674 anesthetics Drugs 0.000 description 2
- 239000003945 anionic surfactant Substances 0.000 description 2
- 239000012062 aqueous buffer Substances 0.000 description 2
- 230000001363 autoimmune Effects 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 239000003114 blood coagulation factor Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- KBPLFHHGFOOTCA-UHFFFAOYSA-N caprylic alcohol Natural products CCCCCCCCO KBPLFHHGFOOTCA-UHFFFAOYSA-N 0.000 description 2
- 229940105270 carbocaine Drugs 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 229960003920 cocaine Drugs 0.000 description 2
- 230000009918 complex formation Effects 0.000 description 2
- 239000000306 component Substances 0.000 description 2
- 230000000139 costimulatory effect Effects 0.000 description 2
- 229960003624 creatine Drugs 0.000 description 2
- 239000006046 creatine Substances 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 210000004443 dendritic cell Anatomy 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 208000037765 diseases and disorders Diseases 0.000 description 2
- 239000012645 endogenous antigen Substances 0.000 description 2
- 210000001163 endosome Anatomy 0.000 description 2
- 238000011067 equilibration Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000003193 general anesthetic agent Substances 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 231100000283 hepatitis Toxicity 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000003960 inflammatory cascade Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 229960002409 mepivacaine Drugs 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 201000006417 multiple sclerosis Diseases 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 201000009240 nasopharyngitis Diseases 0.000 description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
- 208000003154 papilloma Diseases 0.000 description 2
- 244000045947 parasite Species 0.000 description 2
- 229960000244 procainamide Drugs 0.000 description 2
- REQCZEXYDRLIBE-UHFFFAOYSA-N procainamide Chemical compound CCN(CC)CCNC(=O)C1=CC=C(N)C=C1 REQCZEXYDRLIBE-UHFFFAOYSA-N 0.000 description 2
- 229960004919 procaine Drugs 0.000 description 2
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 2
- 244000079416 protozoan pathogen Species 0.000 description 2
- 239000002510 pyrogen Substances 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 229960001549 ropivacaine Drugs 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000009258 tissue cross reactivity Effects 0.000 description 2
- 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 241001529453 unidentified herpesvirus Species 0.000 description 2
- 241000712461 unidentified influenza virus Species 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- LDGWQMRUWMSZIU-LQDDAWAPSA-M 2,3-bis[(z)-octadec-9-enoxy]propyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCCOCC(C[N+](C)(C)C)OCCCCCCCC\C=C/CCCCCCCC LDGWQMRUWMSZIU-LQDDAWAPSA-M 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 241000710929 Alphavirus Species 0.000 description 1
- 208000004881 Amebiasis Diseases 0.000 description 1
- 206010001980 Amoebiasis Diseases 0.000 description 1
- 241001535291 Analges Species 0.000 description 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
- 108020005544 Antisense RNA Proteins 0.000 description 1
- 241000712891 Arenavirus Species 0.000 description 1
- 206010003267 Arthritis reactive Diseases 0.000 description 1
- 201000002909 Aspergillosis Diseases 0.000 description 1
- 208000036641 Aspergillus infections Diseases 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 206010050245 Autoimmune thrombocytopenia Diseases 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 241000711404 Avian avulavirus 1 Species 0.000 description 1
- 241000713826 Avian leukosis virus Species 0.000 description 1
- 208000004429 Bacillary Dysentery Diseases 0.000 description 1
- 241000193738 Bacillus anthracis Species 0.000 description 1
- 108020000946 Bacterial DNA Proteins 0.000 description 1
- 206010044583 Bartonella Infections Diseases 0.000 description 1
- 206010005098 Blastomycosis Diseases 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 208000003508 Botulism Diseases 0.000 description 1
- 241000712005 Bovine respirovirus 3 Species 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 206010006500 Brucellosis Diseases 0.000 description 1
- 206010069748 Burkholderia pseudomallei infection Diseases 0.000 description 1
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 1
- 101710155857 C-C motif chemokine 2 Proteins 0.000 description 1
- 102100032367 C-C motif chemokine 5 Human genes 0.000 description 1
- 208000008889 California Encephalitis Diseases 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 206010007134 Candida infections Diseases 0.000 description 1
- 241000711506 Canine coronavirus Species 0.000 description 1
- 241000701931 Canine parvovirus Species 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 241000700664 Capripoxvirus Species 0.000 description 1
- 241000242722 Cestoda Species 0.000 description 1
- 108010055166 Chemokine CCL5 Proteins 0.000 description 1
- 206010008631 Cholera Diseases 0.000 description 1
- 206010008803 Chromoblastomycosis Diseases 0.000 description 1
- 208000015116 Chromomycosis Diseases 0.000 description 1
- 241001112696 Clostridia Species 0.000 description 1
- 102100022641 Coagulation factor IX Human genes 0.000 description 1
- 241000223205 Coccidioides immitis Species 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 208000009802 Colorado tick fever Diseases 0.000 description 1
- 101710139375 Corneodesmosin Proteins 0.000 description 1
- 241000709687 Coxsackievirus Species 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 201000007336 Cryptococcosis Diseases 0.000 description 1
- 241000221204 Cryptococcus neoformans Species 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- 208000001490 Dengue Diseases 0.000 description 1
- 206010012310 Dengue fever Diseases 0.000 description 1
- 241000710829 Dengue virus group Species 0.000 description 1
- 206010012504 Dermatophytosis Diseases 0.000 description 1
- 208000000655 Distemper Diseases 0.000 description 1
- 102000001039 Dystrophin Human genes 0.000 description 1
- 108010069091 Dystrophin Proteins 0.000 description 1
- 241001115402 Ebolavirus Species 0.000 description 1
- 241001466953 Echovirus Species 0.000 description 1
- 241000588877 Eikenella Species 0.000 description 1
- 206010014596 Encephalitis Japanese B Diseases 0.000 description 1
- 206010014584 Encephalitis california Diseases 0.000 description 1
- 206010014614 Encephalitis western equine Diseases 0.000 description 1
- 206010053025 Endemic syphilis Diseases 0.000 description 1
- 241000588921 Enterobacteriaceae Species 0.000 description 1
- 241000991587 Enterovirus C Species 0.000 description 1
- 206010066919 Epidemic polyarthritis Diseases 0.000 description 1
- 241000186810 Erysipelothrix rhusiopathiae Species 0.000 description 1
- 102000003951 Erythropoietin Human genes 0.000 description 1
- 108090000394 Erythropoietin Proteins 0.000 description 1
- 108090000371 Esterases Proteins 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 108010076282 Factor IX Proteins 0.000 description 1
- 108010071289 Factor XIII Proteins 0.000 description 1
- 241000725579 Feline coronavirus Species 0.000 description 1
- 241000713800 Feline immunodeficiency virus Species 0.000 description 1
- 241000711475 Feline infectious peritonitis virus Species 0.000 description 1
- 241000714165 Feline leukemia virus Species 0.000 description 1
- 241000701925 Feline parvovirus Species 0.000 description 1
- 201000006353 Filariasis Diseases 0.000 description 1
- 241000710831 Flavivirus Species 0.000 description 1
- 241000710198 Foot-and-mouth disease virus Species 0.000 description 1
- 108091006027 G proteins Proteins 0.000 description 1
- 102000030782 GTP binding Human genes 0.000 description 1
- 108091000058 GTP-Binding Proteins 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 206010018612 Gonorrhoea Diseases 0.000 description 1
- 108060003393 Granulin Proteins 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 description 1
- 208000003807 Graves Disease Diseases 0.000 description 1
- 208000015023 Graves' disease Diseases 0.000 description 1
- 206010061192 Haemorrhagic fever Diseases 0.000 description 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 description 1
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 description 1
- 241000724709 Hepatitis delta virus Species 0.000 description 1
- 208000007514 Herpes zoster Diseases 0.000 description 1
- 201000002563 Histoplasmosis Diseases 0.000 description 1
- 101000746373 Homo sapiens Granulocyte-macrophage colony-stimulating factor Proteins 0.000 description 1
- 241000598436 Human T-cell lymphotropic virus Species 0.000 description 1
- 241000701074 Human alphaherpesvirus 2 Species 0.000 description 1
- 241000701024 Human betaherpesvirus 5 Species 0.000 description 1
- 241001207270 Human enterovirus Species 0.000 description 1
- 241000701806 Human papillomavirus Species 0.000 description 1
- 241000726041 Human respirovirus 1 Species 0.000 description 1
- 241000712003 Human respirovirus 3 Species 0.000 description 1
- 241001559187 Human rubulavirus 2 Species 0.000 description 1
- 241001559186 Human rubulavirus 4 Species 0.000 description 1
- 241000711450 Infectious bronchitis virus Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 1
- 201000005807 Japanese encephalitis Diseases 0.000 description 1
- 241000710843 Japanese encephalitis virus group Species 0.000 description 1
- 201000009908 La Crosse encephalitis Diseases 0.000 description 1
- 206010023927 Lassa fever Diseases 0.000 description 1
- 208000004554 Leishmaniasis Diseases 0.000 description 1
- 241000700563 Leporipoxvirus Species 0.000 description 1
- 206010024229 Leprosy Diseases 0.000 description 1
- 102000016267 Leptin Human genes 0.000 description 1
- 108010092277 Leptin Proteins 0.000 description 1
- 206010024238 Leptospirosis Diseases 0.000 description 1
- 241000186781 Listeria Species 0.000 description 1
- 241000186779 Listeria monocytogenes Species 0.000 description 1
- 241000701043 Lymphocryptovirus Species 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 241000711828 Lyssavirus Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001115401 Marburgvirus Species 0.000 description 1
- 241000713821 Mason-Pfizer monkey virus Species 0.000 description 1
- 101710085938 Matrix protein Proteins 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 101710127721 Membrane protein Proteins 0.000 description 1
- 241001460074 Microsporum distortum Species 0.000 description 1
- 241000588621 Moraxella Species 0.000 description 1
- 241000712045 Morbillivirus Species 0.000 description 1
- 241000713333 Mouse mammary tumor virus Species 0.000 description 1
- 241000711386 Mumps virus Species 0.000 description 1
- 241000701034 Muromegalovirus Species 0.000 description 1
- 241000041810 Mycetoma Species 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 206010028470 Mycoplasma infections Diseases 0.000 description 1
- 241000202934 Mycoplasma pneumoniae Species 0.000 description 1
- 208000006007 Nairobi Sheep Disease Diseases 0.000 description 1
- 241000244206 Nematoda Species 0.000 description 1
- 206010029443 Nocardia Infections Diseases 0.000 description 1
- 206010029444 Nocardiosis Diseases 0.000 description 1
- 108091005461 Nucleic proteins Proteins 0.000 description 1
- 101710141454 Nucleoprotein Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 241000702259 Orbivirus Species 0.000 description 1
- 241000150452 Orthohantavirus Species 0.000 description 1
- 241000150218 Orthonairovirus Species 0.000 description 1
- 241000700629 Orthopoxvirus Species 0.000 description 1
- 241001631646 Papillomaviridae Species 0.000 description 1
- 241000606860 Pasteurella Species 0.000 description 1
- 102000002508 Peptide Elongation Factors Human genes 0.000 description 1
- 108010068204 Peptide Elongation Factors Proteins 0.000 description 1
- 208000031845 Pernicious anaemia Diseases 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 241000713137 Phlebovirus Species 0.000 description 1
- 241000709664 Picornaviridae Species 0.000 description 1
- 208000004842 Pinta Diseases 0.000 description 1
- 235000010582 Pisum sativum Nutrition 0.000 description 1
- 240000004713 Pisum sativum Species 0.000 description 1
- 241000233872 Pneumocystis carinii Species 0.000 description 1
- 241001505332 Polyomavirus sp. Species 0.000 description 1
- 241000156302 Porcine hemagglutinating encephalomyelitis virus Species 0.000 description 1
- 241000702619 Porcine parvovirus Species 0.000 description 1
- 229940096437 Protein S Drugs 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 206010037151 Psittacosis Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010037742 Rabies Diseases 0.000 description 1
- 241000701037 Rhadinovirus Species 0.000 description 1
- 208000034712 Rickettsia Infections Diseases 0.000 description 1
- 208000000705 Rift Valley Fever Diseases 0.000 description 1
- 241000710942 Ross River virus Species 0.000 description 1
- 241000710799 Rubella virus Species 0.000 description 1
- 241000710801 Rubivirus Species 0.000 description 1
- 241001533467 Rubulavirus Species 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 241000607768 Shigella Species 0.000 description 1
- 206010040550 Shigella infections Diseases 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 241000710960 Sindbis virus Species 0.000 description 1
- 208000021386 Sjogren Syndrome Diseases 0.000 description 1
- 208000001203 Smallpox Diseases 0.000 description 1
- 101710198474 Spike protein Proteins 0.000 description 1
- 241000605008 Spirillum Species 0.000 description 1
- 206010041736 Sporotrichosis Diseases 0.000 description 1
- 206010041896 St. Louis Encephalitis Diseases 0.000 description 1
- 241000710888 St. Louis encephalitis virus Species 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 241001478880 Streptobacillus moniliformis Species 0.000 description 1
- 241000700568 Suipoxvirus Species 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- 208000000389 T-cell leukemia Diseases 0.000 description 1
- 208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 description 1
- 108020005038 Terminator Codon Proteins 0.000 description 1
- 206010043376 Tetanus Diseases 0.000 description 1
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 description 1
- 208000002474 Tinea Diseases 0.000 description 1
- 201000005485 Toxoplasmosis Diseases 0.000 description 1
- 241000242541 Trematoda Species 0.000 description 1
- 241000869417 Trematodes Species 0.000 description 1
- 206010044608 Trichiniasis Diseases 0.000 description 1
- 208000034784 Tularaemia Diseases 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 206010046865 Vaccinia virus infection Diseases 0.000 description 1
- 241000701067 Varicellovirus Species 0.000 description 1
- 241000870995 Variola Species 0.000 description 1
- 241000700647 Variola virus Species 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- 241000711975 Vesicular stomatitis virus Species 0.000 description 1
- 241000711970 Vesiculovirus Species 0.000 description 1
- 108700005077 Viral Genes Proteins 0.000 description 1
- 208000005466 Western Equine Encephalomyelitis Diseases 0.000 description 1
- 201000005806 Western equine encephalitis Diseases 0.000 description 1
- 208000003152 Yellow Fever Diseases 0.000 description 1
- 241000120645 Yellow fever virus group Species 0.000 description 1
- 241000607734 Yersinia <bacteria> Species 0.000 description 1
- 206010061418 Zygomycosis Diseases 0.000 description 1
- 201000007691 actinomycosis Diseases 0.000 description 1
- 208000012873 acute gastroenteritis Diseases 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000002223 anti-pathogen Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000000074 antisense oligonucleotide Substances 0.000 description 1
- 238000012230 antisense oligonucleotides Methods 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 201000008680 babesiosis Diseases 0.000 description 1
- 206010004145 bartonellosis Diseases 0.000 description 1
- 229960005274 benzocaine Drugs 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 239000012503 blood component Substances 0.000 description 1
- 208000003836 bluetongue Diseases 0.000 description 1
- 108010006025 bovine growth hormone Proteins 0.000 description 1
- 239000003560 cancer drug Substances 0.000 description 1
- 201000003984 candidiasis Diseases 0.000 description 1
- 208000014058 canine distemper Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000003093 cationic surfactant Substances 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 210000002230 centromere Anatomy 0.000 description 1
- 201000004308 chancroid Diseases 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 229960002023 chloroprocaine Drugs 0.000 description 1
- VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 description 1
- 239000013611 chromosomal DNA Substances 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 201000003486 coccidioidomycosis Diseases 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 230000000536 complexating effect Effects 0.000 description 1
- 201000003740 cowpox Diseases 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 201000003278 cryoglobulinemia Diseases 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 208000025729 dengue disease Diseases 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 201000001981 dermatomyositis Diseases 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 206010013023 diphtheria Diseases 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007515 enzymatic degradation Effects 0.000 description 1
- 229940105423 erythropoietin Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 229960004222 factor ix Drugs 0.000 description 1
- 229940012444 factor xiii Drugs 0.000 description 1
- 235000019688 fish Nutrition 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 244000053095 fungal pathogen Species 0.000 description 1
- 230000000799 fusogenic effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000001476 gene delivery Methods 0.000 description 1
- 238000010448 genetic screening Methods 0.000 description 1
- 201000006592 giardiasis Diseases 0.000 description 1
- 208000001786 gonorrhea Diseases 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 244000000013 helminth Species 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- KLHSDMQFUVANEB-MELZOAELSA-L hexadecyl-[(2r,3r)-4-[hexadecyl(dimethyl)azaniumyl]-2,3-dimethoxybutyl]-dimethylazanium;dibromide Chemical compound [Br-].[Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C[C@@H](OC)[C@H](OC)C[N+](C)(C)CCCCCCCCCCCCCCCC KLHSDMQFUVANEB-MELZOAELSA-L 0.000 description 1
- 244000052637 human pathogen Species 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 150000002433 hydrophilic molecules Chemical class 0.000 description 1
- 239000012216 imaging agent Substances 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000001024 immunotherapeutic effect Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 229940039781 leptin Drugs 0.000 description 1
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 150000004668 long chain fatty acids Chemical class 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 208000001581 lymphogranuloma venereum Diseases 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 201000004015 melioidosis Diseases 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 201000007524 mucormycosis Diseases 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 201000006938 muscular dystrophy Diseases 0.000 description 1
- 206010028417 myasthenia gravis Diseases 0.000 description 1
- TVMXDCGIABBOFY-UHFFFAOYSA-N n-Octanol Natural products CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 201000000901 ornithosis Diseases 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 230000009984 peri-natal effect Effects 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 208000011079 pinta disease Diseases 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 208000005987 polymyositis Diseases 0.000 description 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 235000013594 poultry meat Nutrition 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 208000009305 pseudorabies Diseases 0.000 description 1
- 208000002574 reactive arthritis Diseases 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012502 risk assessment Methods 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 201000000306 sarcoidosis Diseases 0.000 description 1
- 201000004409 schistosomiasis Diseases 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 201000005113 shigellosis Diseases 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 208000006379 syphilis Diseases 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 150000004579 taxol derivatives Chemical class 0.000 description 1
- 102000055501 telomere Human genes 0.000 description 1
- 108091035539 telomere Proteins 0.000 description 1
- 210000003411 telomere Anatomy 0.000 description 1
- 241001147422 tick-borne encephalitis virus group Species 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000037317 transdermal delivery Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 208000003982 trichinellosis Diseases 0.000 description 1
- 201000007588 trichinosis Diseases 0.000 description 1
- 201000002311 trypanosomiasis Diseases 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 241001148471 unidentified anaerobic bacterium Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 208000007089 vaccinia Diseases 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- 229960004854 viral vaccine Drugs 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 201000009482 yaws Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/70—Nanostructure
- Y10S977/773—Nanoparticle, i.e. structure having three dimensions of 100 nm or less
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/902—Specified use of nanostructure
- Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
- Y10S977/905—Specially adapted for travel through blood circulatory system
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/902—Specified use of nanostructure
- Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
- Y10S977/906—Drug delivery
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/902—Specified use of nanostructure
- Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
- Y10S977/906—Drug delivery
- Y10S977/907—Liposome
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/902—Specified use of nanostructure
- Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
- Y10S977/915—Therapeutic or pharmaceutical composition
- Y10S977/916—Gene therapy
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Dispersion Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US4512297P | 1997-04-30 | 1997-04-30 | |
| US60/045,122 | 1997-04-30 | ||
| PCT/US1998/008799 WO1998048780A1 (en) | 1997-04-30 | 1998-04-30 | Vesicular complexes and methods of making and using the same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2285298A1 CA2285298A1 (en) | 1998-11-05 |
| CA2285298C true CA2285298C (en) | 2008-12-23 |
Family
ID=21936112
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA 2285298 Expired - Fee Related CA2285298C (en) | 1997-04-30 | 1998-04-30 | Complexes comprising local anesthetic and nucleic acid and method of making and using the same |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US6217900B1 (enExample) |
| EP (1) | EP0986372B1 (enExample) |
| JP (1) | JP2002508747A (enExample) |
| KR (1) | KR100554344B1 (enExample) |
| CN (1) | CN1092045C (enExample) |
| AT (1) | ATE446372T1 (enExample) |
| AU (1) | AU728115C (enExample) |
| BR (1) | BR9809006B1 (enExample) |
| CA (1) | CA2285298C (enExample) |
| DE (1) | DE69841251D1 (enExample) |
| ES (1) | ES2333282T3 (enExample) |
| WO (1) | WO1998048780A1 (enExample) |
Families Citing this family (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69942581D1 (de) * | 1998-05-25 | 2010-08-26 | Nippon Shinyaku Co Ltd | Verfahren zur herstellung einer nucleinsäure enthaltenden kompositzusammenstellung |
| CA2361201A1 (en) * | 1999-01-28 | 2000-08-03 | Medical College Of Georgia Research Institute, Inc. | Composition and method for in vivo and in vitro attenuation of gene expression using double stranded rna |
| EP1097993A3 (en) * | 1999-11-05 | 2004-01-07 | National Institute of Advanced Industrial Science and Technology | Functional ribozyme chimeric molecules capable of sliding |
| US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
| CA2474822A1 (en) * | 2002-02-07 | 2003-08-14 | University Of Utah Research Foundation | Method for creating and using a treatment protocol |
| US20040180438A1 (en) * | 2002-04-26 | 2004-09-16 | Pachuk Catherine J. | Methods and compositions for silencing genes without inducing toxicity |
| JP4868739B2 (ja) * | 2002-05-06 | 2012-02-01 | アルナイラム ファーマシューティカルズ， インコーポレイテッド | 核酸の送達法 |
| JP2005529959A (ja) * | 2002-06-14 | 2005-10-06 | マイラス コーポレイション | 細胞へのポリヌクレオチドの伝達をするための新規な方法 |
| WO2004011624A2 (en) * | 2002-07-31 | 2004-02-05 | Nucleonics, Inc. | Double stranded rna structures and constructs, and methods for generating and using the same |
| WO2004073631A2 (en) * | 2003-02-14 | 2004-09-02 | Combinatorx, Incorporated | Combination therapy for the treatment of neoplasms |
| CA3040025C (en) | 2003-06-12 | 2023-01-10 | Alnylam Pharmaceuticals, Inc. | Conserved hbv and hcv sequences useful for gene silencing |
| TW200613554A (en) | 2004-06-17 | 2006-05-01 | Wyeth Corp | Plasmid having three complete transcriptional units and immunogenic compositions for inducing an immune response to HIV |
| EP2325314B1 (en) | 2004-09-24 | 2014-08-20 | Alnylam Pharmaceuticals, Inc. | Targeting opposite strand replication intermediates of single-stranded viruses by RNAI |
| AU2005319306B9 (en) | 2004-12-22 | 2012-04-05 | Alnylam Pharmaceuticals, Inc. | Conserved HBV and HCV sequences useful for gene silencing |
| PT1912675E (pt) | 2005-07-25 | 2014-05-09 | Emergent Product Dev Seattle | Moléculas de ligaçao especificas para cd37 e especificas para cd20 |
| MX380352B (es) | 2006-06-12 | 2025-03-12 | Aptevo Res & Development Llc | Proteinas de union multivalentes monocatenarias con funcion efectora. |
| CN101541950A (zh) | 2006-07-13 | 2009-09-23 | 惠氏公司 | 糖蛋白的产生 |
| DK2548438T3 (en) | 2006-11-08 | 2015-10-19 | Veritas Bio LLC | IN VIVO SUBMITTING DOUBLE-STRENGTH RNA TO A CELL |
| CN101990439A (zh) * | 2007-07-06 | 2011-03-23 | 特鲁比昂药品公司 | 具有置于c末端的特异性结合结构域的结合肽 |
| RS51975B (sr) | 2008-04-11 | 2012-02-29 | Emergent Product Development Seattle Llc. | Cd37 imunoterapeutski proizvod i njegova kombinacija sa bifunkcionalnim hemoterapeutskim sredstvom |
| CA2761106C (en) | 2009-05-05 | 2019-01-15 | Miragen Therapeutics | Lipophilic polynucleotide conjugates |
| AU2010258875A1 (en) | 2009-06-08 | 2012-01-19 | Miragen Therapeutics | Chemical modification motifs for miRNA inhibitors and mimetics |
| NZ602538A (en) * | 2010-04-01 | 2014-03-28 | Pharmanest Ab | Thermogelling anaesthetic compositions |
| EP2635681B8 (en) | 2010-11-05 | 2017-10-04 | Miragen Therapeutics, Inc. | Base modified oligonucleotides |
| AR084319A1 (es) | 2010-12-15 | 2013-05-08 | Miragen Therapeutics | INHIBIDORES DE microARN (miARN O miR) QUE COMPRENDEN NUCLEOTIDOS BLOQUEADOS |
| AU2012242761A1 (en) | 2011-04-12 | 2013-10-31 | Beth Israel Deaconess Medical Center, Inc. | Micro-RNA inhibitors and their uses in disease |
| US9018188B2 (en) | 2011-09-13 | 2015-04-28 | Ottawa Hospital Research Institute | MicroRNA inhibitors |
| CN104685056A (zh) | 2012-06-21 | 2015-06-03 | 米拉根医疗股份有限公司 | 包含锁核酸基序的基于寡核苷酸的抑制剂 |
| CA2902571A1 (en) | 2013-03-15 | 2014-09-18 | MiRagen Therapeutics, Inc. | Bridged bicyclic nucleosides |
| US10172916B2 (en) | 2013-11-15 | 2019-01-08 | The Board Of Trustees Of The Leland Stanford Junior University | Methods of treating heart failure with agonists of hypocretin receptor 2 |
| US10772974B2 (en) | 2013-11-18 | 2020-09-15 | Beth Israel Deaconess Medical Center, Inc. | Compositions and methods for cardiac regeneration |
| JP6637961B2 (ja) | 2014-08-04 | 2020-01-29 | ミラゲン セラピューティクス， インコーポレイテッド | Ｍｙｈ７ｂの阻害剤およびその使用 |
| JP6837963B2 (ja) | 2014-09-08 | 2021-03-03 | ミラゲン セラピューティクス， インコーポレイテッド | Ｍｉｒ−２９模倣物およびその使用 |
| JP2018503646A (ja) | 2015-01-20 | 2018-02-08 | ミラゲン セラピューティクス， インコーポレイテッド | ｍｉＲ−９２阻害剤およびその使用 |
| WO2016197024A2 (en) | 2015-06-05 | 2016-12-08 | MiRagen Therapeutics, Inc. | Mir-155 inhibitors for treating cutaneous t cell lymphoma (ctcl) |
| BR112018005573A2 (pt) | 2015-09-21 | 2019-01-22 | Aptevo Research And Development Llc | ?polipeptídeos de ligação a cd3? |
| US10357543B2 (en) | 2015-11-16 | 2019-07-23 | Ohio State Innovation Foundation | Methods and compositions for treating disorders and diseases using Survival Motor Neuron (SMN) protein |
| NZ749593A (en) | 2016-06-20 | 2025-10-31 | Univ Leland Stanford Junior | Circular rnas and their use in immunomodulation |
| UY37376A (es) | 2016-08-26 | 2018-03-23 | Amgen Inc | Construcciones de arni para inhibir expresión de asgr1 y métodos para su uso |
| ES2659845B1 (es) | 2016-09-19 | 2019-01-04 | Univ Valencia | Modulación de microRNAs contra la distrofia miotónica tipo 1 y antagonistas de microRNAs para ello |
| UY38003A (es) | 2017-12-12 | 2019-06-28 | Amgen Inc | Construcciones de arni para inhibir la expresión de pnpla3 y métodos de uso de las mismas |
| EP3765619B1 (en) | 2018-03-14 | 2024-10-09 | Beth Israel Deaconess Medical Center | Inhibitors of micro-rna 22 |
| KR20210102932A (ko) | 2018-12-10 | 2021-08-20 | 암젠 인크 | Pnpla3 발현을 억제하기 위한 rnai 작제물 및 이의 사용 방법 |
| JP2022511866A (ja) | 2018-12-10 | 2022-02-01 | アムジエン・インコーポレーテツド | 化学修飾されたＲＮＡｉコンストラクト及びその使用 |
| TW202111124A (zh) | 2019-05-30 | 2021-03-16 | 美商安進公司 | 用於抑制ｓｃａｐ表現之ｒｎａｉ構建體及其使用方法 |
| CA3150758A1 (en) | 2019-08-13 | 2021-02-18 | Amgen Inc. | Rnai constructs for inhibiting slc30a8 expression and methods of use thereof |
| US20230078200A1 (en) | 2019-12-09 | 2023-03-16 | Amgen Inc. | RNAi CONSTRUCTS AND METHODS FOR INHIBITING LPA EXPRESSION |
| WO2021234607A1 (en) | 2020-05-20 | 2021-11-25 | St. Jude Children's Research Hospital | Detection of alzheimer's disease using specific biomarkers |
| US20230279399A1 (en) | 2020-06-01 | 2023-09-07 | Amgen Inc. | Rnai constructs for inhibiting hsd17b13 expression and methods of use thereof |
| EP3929295A1 (en) | 2020-06-26 | 2021-12-29 | Universitat Pompeu Fabra | Artificial rnas for modulating rna fragments |
| CR20230126A (es) | 2020-08-13 | 2023-05-03 | Amgen Inc | CONSTRUCCIONES DE iARN Y MÉTODOS PARA INHIBIR LA EXPRESIÓN DE MARC1 |
| KR20230104200A (ko) | 2020-11-05 | 2023-07-07 | 암젠 인크 | LPA-표적화된 RNAi 작제물을 이용하여 죽상경화성 심혈관질환을 치료하는 방법 |
| WO2023278295A1 (en) | 2021-06-29 | 2023-01-05 | The Broad Institute, Inc. | Compositions and methods for ameliorating anterodorsal thalamus hyperexcitability |
| CA3234369A1 (en) | 2021-10-05 | 2023-04-13 | Amgen Inc. | Compositions and methods for enhancing gene silencing activity of oligonucleotide compounds |
| WO2023069754A2 (en) | 2021-10-22 | 2023-04-27 | Amgen Inc. | Rnai constructs for inhibiting gpam expression and methods of use thereof |
| IL317825A (en) | 2022-07-25 | 2025-02-01 | Amgen Inc | RNA interference constructs and methods for inhibiting fam13a expression |
| EP4353823A1 (en) | 2022-10-12 | 2024-04-17 | Resalis Therapeutics S.r.l. | Inhibitors of micro-rna 22 |
| IL321194A (en) | 2022-12-16 | 2025-07-01 | Amgen Inc | RNA interference constructs for inhibiting TTR expression and methods for using them |
| WO2025260042A1 (en) | 2024-06-14 | 2025-12-18 | Amgen Inc. | Rnai constructs and methods for inhibiting cnr1 expression |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4945050A (en) | 1984-11-13 | 1990-07-31 | Cornell Research Foundation, Inc. | Method for transporting substances into living cells and tissues and apparatus therefor |
| US5948441A (en) * | 1988-03-07 | 1999-09-07 | The Liposome Company, Inc. | Method for size separation of particles |
| US5514788A (en) | 1993-05-17 | 1996-05-07 | Isis Pharmaceuticals, Inc. | Oligonucleotide modulation of cell adhesion |
| US5593972A (en) | 1993-01-26 | 1997-01-14 | The Wistar Institute | Genetic immunization |
| DE69434469T2 (de) * | 1993-01-26 | 2006-06-14 | Univ Pennsylvania | Zusammensetzungen und verfahren zur verabreichung von genetischem material |
| WO1996021015A2 (en) * | 1994-12-30 | 1996-07-11 | Chiron Corporation | Combination gene delivery vehicles |
| KR20140137679A (ko) | 2013-05-23 | 2014-12-03 | 삼성전자주식회사 | 카드 소켓 장치 |
-
1997
- 1997-04-30 US US09/402,507 patent/US6217900B1/en not_active Expired - Fee Related
-
1998
- 1998-04-30 AT AT98920077T patent/ATE446372T1/de not_active IP Right Cessation
- 1998-04-30 ES ES98920077T patent/ES2333282T3/es not_active Expired - Lifetime
- 1998-04-30 WO PCT/US1998/008799 patent/WO1998048780A1/en not_active Ceased
- 1998-04-30 JP JP54741798A patent/JP2002508747A/ja active Pending
- 1998-04-30 AU AU72724/98A patent/AU728115C/en not_active Ceased
- 1998-04-30 CN CN98810484A patent/CN1092045C/zh not_active Expired - Fee Related
- 1998-04-30 DE DE69841251T patent/DE69841251D1/de not_active Expired - Lifetime
- 1998-04-30 KR KR1019997009723A patent/KR100554344B1/ko not_active Expired - Fee Related
- 1998-04-30 CA CA 2285298 patent/CA2285298C/en not_active Expired - Fee Related
- 1998-04-30 BR BRPI9809006-2A patent/BR9809006B1/pt not_active IP Right Cessation
- 1998-04-30 EP EP19980920077 patent/EP0986372B1/en not_active Expired - Lifetime
-
2000
- 2000-04-04 US US09/542,409 patent/US6383512B1/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| KR100554344B1 (ko) | 2006-02-22 |
| ES2333282T3 (es) | 2010-02-18 |
| BR9809006B1 (pt) | 2010-02-09 |
| AU728115C (en) | 2004-01-22 |
| DE69841251D1 (de) | 2009-12-03 |
| US6217900B1 (en) | 2001-04-17 |
| AU7272498A (en) | 1998-11-24 |
| KR20010020161A (ko) | 2001-03-15 |
| AU728115B2 (en) | 2001-01-04 |
| EP0986372A1 (en) | 2000-03-22 |
| BR9809006A (pt) | 2000-08-08 |
| WO1998048780A1 (en) | 1998-11-05 |
| CA2285298A1 (en) | 1998-11-05 |
| JP2002508747A (ja) | 2002-03-19 |
| EP0986372B1 (en) | 2009-10-21 |
| CN1277549A (zh) | 2000-12-20 |
| CN1092045C (zh) | 2002-10-09 |
| US6383512B1 (en) | 2002-05-07 |
| ATE446372T1 (de) | 2009-11-15 |
| EP0986372A4 (en) | 2002-06-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2285298C (en) | Complexes comprising local anesthetic and nucleic acid and method of making and using the same | |
| EP1976871B1 (en) | Vaccines and immunotherapeutics using codon optimized il-15 and methods for using the same | |
| US6379965B1 (en) | Multifunctional complexes for gene transfer into cells comprising a nucleic acid bound to a polyamine and having an endosome disruption agent | |
| US9629907B2 (en) | Compositions for and methods of inducing mucosal immune responses | |
| EP1355628A2 (en) | Stabilised polymeric aerosols for pulmonary gene delivery | |
| EP1633372B1 (en) | Vaccines, immunotherapeutics and methods for using the same | |
| EP1257298B1 (en) | Cosmid dna constructs and methods of making and using the same | |
| CA2408403A1 (en) | Vaccines, immunotherapeutics and methods for using the same | |
| WO1999064074A1 (en) | Methods and compositions for delivering proteins to macrophage cells and cells of macrophage derived lineage | |
| Dijkstra et al. | Volume I: Molecular Biochemistry and Cellular Biology 329 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |
Effective date: 20130430 |